Preclinical evaluation of binimetinib (MEK162) delivered via polymeric nanocarriers in combination with radiation and temozolomide in glioma
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Neuro-Oncology"
DOI: 10.1007/s11060-019-03365-y
Abstract: Background and purpose Glioblastoma multiforme (GBM) is the most aggressive subtype of malignant gliomas, with an average survival rate of 15 months after diagnosis. More than 90% of all GBMs have activating mutations in the MAPK/ERK… read more here.
Keywords: delivered via; binimetinib mek162; polymeric nanocarriers; mek162 delivered ... See more keywords